Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domagrozumab in Ambulatory Boys with Duchenne Muscular Dystrophy
NCT02310763Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2014
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of domagrozumab in Duchenne muscular dystrophy (DMD), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events at 49 weeks and Change From Baseline on the 4 Stair Climb at 49 weeks. Started Nov 2014; status: terminated.
02
Drugs
domagrozumab
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02310763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02310763.